Regulus Therapeutics Inc.’s RGLS share price has surged by 16.28%, which has investors questioning if this is right time to ...
Regulus Therapeutics' Phase 1b study shows farabursen 300 mg slowed kidney volume growth in ADPKD patients with a favorable ...
Regulus Therapeutics (RGLS) stock soars after positive Phase 1b trial data for the company's lead asset, farabursen against a ...
Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.4% following an upgrade from Wells Fargo analyst ...
Investing.com -- Shares of Regulus Therapeutics (NASDAQ: RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...
DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and ...
After hours: March 24 at 4:57:28 PM EDT Vertex Baseline Delta ...
Soleno Therapeutics SLNO shares increased by 38.8% to $67.98 during Thursday's pre-market session. The company's market cap stands at $2.9 billion. Ocean Biomedical OCEA shares moved upwards by 23.05% ...